Biotech Catalyst Monitor: Clinical Trial Readouts and Pipeline Data
Track the clinical-trial events that often move biotech stocks. Provide one or more company names and get their trials from ClinicalTrials.gov, ranked by potential market impact: upcoming Phase 3 readouts, results just posted and phase transitions. A curated catalyst dataset, not a raw trial dump.
What it does
- Catalyst classification: upcoming readout, results posted, completed-awaiting-results, status change.
- Impact score 0-100: later phases and near-term readouts rank highest.
- Per-company ranking of the trials most likely to be market-moving.
- A direct ClinicalTrials.gov link for every catalyst.
Who uses clinical-trial data
- Biotech investors and traders building a catalyst calendar.
- Fintech and research apps embedding pipeline data.
- Pharma competitive-intelligence teams tracking a competitor’s pipeline and readout timing.
How it works
The tool reads the official ClinicalTrials.gov v2 API (free, public, JSON), matches the sponsor field with a full-text fallback, then classifies and scores each trial. Clean and stable.
Example
Moderna top catalyst in live data: a Phase 3 trial, active, with primary completion 2026-06-30, impact score 100 (an upcoming readout).
FAQ
Which companies can I track? Any sponsor in ClinicalTrials.gov. Use the company name. How current is it? ClinicalTrials.gov is the official U.S. registry, updated continuously. Is this investment advice? No. It is data for research and monitoring. A single readout can move a stock sharply, but historical patterns do not guarantee future results.
Related
Keywords: clinical trials, biotech catalyst, trial readout, PDUFA, phase 3 results, ClinicalTrials.gov API, biotech investing, catalyst calendar, drug pipeline, pharma intelligence.